Circulating Tumor DNA (ctDNA) Dynamic Monitoring Plus Artificial Intelligence (AI)-Based Pathology Predict the Efficacy of Chemoimmunotherapy in Resectable Lung Squamous Cell Carcinoma (LSCC)

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Histopathology or cytology confirmed the lung squamous cell carcinoma

• Age ranging from 18 to 75

• Agree to participate in this study and sign an informed consent form

• Treatment-naive tumor

• According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor

• Sufficient tissue/blood samples are available to meet research requirements

• The ECOG PS score is 0-1

Locations
Other Locations
China
Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China
RECRUITING
Changsha
Contact Information
Primary
Yan Hu, M.D., Ph.D.
yanhu@csu.edu.cn
8685296122
Time Frame
Start Date: 2023-03-23
Estimated Completion Date: 2029-09-23
Participants
Target number of participants: 50
Treatments
Patients with lung Squamous Cell Carcinoma receiving neoadjuvant chemoimmunotherapy
Related Therapeutic Areas
Squamous Cell Lung Carcinoma
Sponsors
Collaborators: Shanghai OrigiMed Co., Ltd.
Leads: Second Xiangya Hospital of Central South University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma

A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma

Enrollment Status: Recruiting
Publish Date: May 30, 2024
Intervention Type: Other

An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab

An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab

Who is this study for: Patients with head and neck squamous cell carcinoma, non-small cell lung cancer or melanoma who are treated with ezabenlimab
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063, BI 770371, [89Zr]Zr- BI 770371
Study Phase: Phase 1

Bronchial Arterial Infusion Plus Bronchial Arterial Chemoembolization (BAI-BACE) for Advanced Lung Squamous Cell Carcinoma: a Multicenter Single-arm Phase II Study

Bronchial Arterial Infusion Plus Bronchial Arterial Chemoembolization (BAI-BACE) for Advanced Lung Squamous Cell Carcinoma: a Multicenter Single-arm Phase II Study

Enrollment Status: Recruiting
Publish Date: August 09, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
View All